

IMPORTANT INFORMATION

This presentation (**Presentation**) contains summary information about Cellular Goods PLC (**Company**) which is current as at 27 April 2022. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

Summary information - This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with the Company's most recent financial report and other periodic disclosure released via a Regulatory Information Service. Reliance should not be placed on information or opinions contained in this Presentation and, subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation.

Forward looking statements – This Presentation contains statements that are or may be deemed to be "forward-looking statements", which relate, among other things, to the Company's proposed strategy, plans and objectives. Forward-looking statements are sometimes identified by the use of terminology such as "believes", "expects", "may", "will", "could", "should" "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positions" or "anticipates" or the negatives thereof, other variations thereon or comparable terminology. Such forward-looking statements include all matters that are not historical facts. They appear in a number of places in the Presentation and include statements regarding the intentions, beliefs or current expectations of the current directors of the Company concerning, among other things, the results of operations, financial conditions, liquidity, prospects, growth, and strategies of the Company and the industry in which it operates. By its nature, such forward-looking information requires the Company to make assumptions that may or may not materialise. Such forward-looking statements may involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such forward-looking statements. Forward-looking statements are not guarantees of future performance and may prove to be erroneous. The Company's actual results of operations, financial condition and prospects, liquidity, dividend policy and the development of the industry, markets and sectors in which it operates may differ materially from the impression created by forward-looking statements contained in the Presentation. Past performance of the Company cannot be relied upon as a guide to future performance. No statement in the Presentation is intended as a profit forecast or a profit estimate.

Financial information - This Presentation contains historical financial information based on the Company's results for the 12 month period ending 31 August 2021. All financial information disclosed in this Presentation is presented in pounds sterling unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding.

Disclaimer - To the maximum extent permitted by law, the Company and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about the Company or that a purchaser may require in evaluating a possible investment in the Company, or the likelihood of fulfilment of any forward-looking statement.



The market opportunity for cannabinoids is strong

£1bn by 2025*









Who we are and why we exist

We are a premium wellness company. We exist in order to bring clarity and authority to the world of wellness and we do this through science-backed and efficacy-led products based on lab-made cannabinoids. We empower our customers to feel, look and function better.











Vegan



High Performance

Cruelty Free

Pure Cannabinoids

Eco Friendly





Cellular Goods offer is differentiated vs the market

Cellular Goods

The Market

POSITIONING Wellness Health or Beauty

CANNABINOIDS ORIGIN

Lab-made yet natural (biosynthesis)

Plant

QUALITY

Consistent

Inconsistent (only 38% within 10% of the claimed amount of CBD)


CLAIMS Science-backed Lifestyle

ENVIRONMENTAL FOOTPRINT Planet-friendly Significant carbon footprint

*Source: Centre for Medicinal Cannabis, 2019



Good progress since the IPO: introduced 6 products, expanded sales channels, launched scientific credentials, and started marketing



Product landed well with consumers



Cellular Goods

Reviews 36 • Excellent











22 Jan 2022

The face oil is fab

The face oil is fab, have noticed a real difference in my skin, looks and feel more radiant and youthful, will buy again but hoping maybe their will be some offers or discounts available to repurchase.





Investment in science is paying out: Cellular is unique in the UK with CBG, a novel cannabinoid that rivals the leading anti-ageing ingredients.

- White paper 'Cannabinoids for the Prevention of Aging' went live in February proving the business case for cannabinoids use in Skincare.

 Opportunity to tap into \$47.8 bn Global anti-ageing market.
- We invested significantly in research and development to date and will continue to do this in order to further cannabinoids understanding

BEAUTY & SKINCARE

CBD and CBG show potential for fighting signs of ageing

It's the second paper in recent weeks that recommends the use of CBD and CBG in skincare




Published 5 days agoon 2nd February 2022 By Caroline Barry



Marketing investment drove strong visibility for Cellular Goods

Share of voice, Q1 2022







What's next: 5-year strategy

Help the World uncover the wellness power of cannabinoids.

VISION

Establish market leading wellness brand powered by the science of cannabinoids

GOAL

1. Focus on products that meaningfully make people Feel Better, Look Better, Function Better

STRATEGIES

- 2. Invest in education and awareness
- 3. Omnichannel Go-To-Market
- 4. Geographical expansion: UK in Year 1, EU in Y2, rest of the World Y3+



Our Innovation Plan is strong, aligned with consumer needs and provides competitive cadence.

	2021	2022			2023				
	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
FEEL BETTER: Supplements - led	Oral Spray Oral Drops Capsules				Gifting		New formats and occasions		Gifting
LOOK BETTER: Skin-led	Face Oil After Shaving Moisturiser	Serum	Travel Sizes & Samples	Line extension	Gifting	Line extension		Line extension	Gifting
FUNCTION BETTER: Recovery - led						Recovery range launch		Line extension	Gifting






Our second white paper furthers Cellular image as industry future forward player by making the case for lab-made vs plant-grown cannabinoids








We will continue to invest in marketing

Consumer Purchase Funnel







We will pursue distribution opportunities



In Summary: the market opportunity remains strong and Cellular Goods is well placed to take advantage of it

- 6 million people in the UK have tried CBD, 1.2 million use CBD products regularly.
- No signs of saturation: UK market has doubled year-on-year for the past 3 years and is expected to be worth almost £1bn a year by 2025.
- Yet no brand leader emerged yet.



Cellular Goods opportunity






INNOVATION UPDATE

Investing in the future of cannabinoid consumer products


April 27th, 2022





Cannabinoids 101


Unlocking nature's most powerful ingredients






Insight #1) A sustainable cannabinoid future

Repurposing well-established technology as a superior method of cannabinoid production



BIOSYNTHESIS (FERMENTATION)

- ✓ Scalable
- ✓ Clean
- ✓ Consistent
- ✓ Sustainable
- ✓ Access to minor cannabinoids
- ✓ Rapid manufacturing process



^{*}Source: Environmental performance comparison - Willow Biosciences Corporate Presentation March 2022




Insight #2) Skincare is the new frontier

Leveraging proprietary research to provide new benefits

New Research: CBG and CBD protect against the aging effects of UV and inflammation

New Claims: Clinical testing confirming age-prevention, soothing and anti-blemish properties of CBG








Insight #3) CBD for recovery is just the beginning

Leveraging proprietary research to provide new benefits

CBGA and CBG inhibit COX-2 equivalent to ibuprofen

Test Material	IC ₅₀ (μΜ)	Maximum Inhibition (%)
Diclofenac (positive control)	0.036	98 ± 3
Ibuprofen (from literature)	370	-
CBG	583	61 ± 16
CBGA	340	80 ± 10
CBD	> 1000	0
CBDA	> 1000	27 ± 24

Skin permeation assessments for CBD formulas



CBG and CBD inhibit the growth of odor-causing bacteria

